S Fickert1, T Schattenberg, M Niks, C Weiss, S Thier. 1. Orthopaedic and Trauma Surgery Center, University Medical Centre Mannheim, University of Heidelberg, Theodor Kutzer Ufer 1-3, 68167, Mannheim, Germany.
Abstract
INTRODUCTION: The purpose of this retrospective study was to describe technical aspects of arthroscopic, purely autologous chondrocyte transplantation of the hip and to report short-term data of the postoperative outcome in a consecutive series of patients. MATERIALS AND METHODS: We retrospectively analyzed six patients with a full-thickness chondral defect of the hip joint. The defect was treated with an arthroscopically applicable 3-dimensional purely autologous chondrocyte transplant product (chondrosphere(®); co.don(®) AG, Berlin, Germany) in a two-step surgical procedure. Patient-administered scores were assessed at baseline (day before transplantation) and at 6 weeks, 3, 6 and 12 months. RESULTS: Six out of six initially included patients (five males, one female) with a median age of 32.5 years and an average defect size of 3.5 cm(2) were available for follow-up after a mean of 11.2 months. Five acetabular and one femoral defect were treated. An overall statistically significant improvement was observed for all assessment scores (NHS, mHHS and SF 36). CONCLUSION: In this study, we displayed the feasibility and technical aspects of arthroscopic matrix-associated, purely autologous chondrocyte transplantation as a treatment option for full-thickness cartilage defects of the hip. The patient-administered assessment scores demonstrated an increase in activity level and quality of life after a 1-year follow-up. LEVEL OF EVIDENCE: Level IV, retrospective study.
INTRODUCTION: The purpose of this retrospective study was to describe technical aspects of arthroscopic, purely autologous chondrocyte transplantation of the hip and to report short-term data of the postoperative outcome in a consecutive series of patients. MATERIALS AND METHODS: We retrospectively analyzed six patients with a full-thickness chondral defect of the hip joint. The defect was treated with an arthroscopically applicable 3-dimensional purely autologous chondrocyte transplant product (chondrosphere(®); co.don(®) AG, Berlin, Germany) in a two-step surgical procedure. Patient-administered scores were assessed at baseline (day before transplantation) and at 6 weeks, 3, 6 and 12 months. RESULTS: Six out of six initially included patients (five males, one female) with a median age of 32.5 years and an average defect size of 3.5 cm(2) were available for follow-up after a mean of 11.2 months. Five acetabular and one femoral defect were treated. An overall statistically significant improvement was observed for all assessment scores (NHS, mHHS and SF 36). CONCLUSION: In this study, we displayed the feasibility and technical aspects of arthroscopic matrix-associated, purely autologous chondrocyte transplantation as a treatment option for full-thickness cartilage defects of the hip. The patient-administered assessment scores demonstrated an increase in activity level and quality of life after a 1-year follow-up. LEVEL OF EVIDENCE: Level IV, retrospective study.
Authors: Ekaterina V Medvedeva; Ekaterina A Grebenik; Svetlana N Gornostaeva; Vladimir I Telpuhov; Aleksey V Lychagin; Peter S Timashev; Andrei S Chagin Journal: Int J Mol Sci Date: 2018-08-11 Impact factor: 5.923